Special Issue "Kinase Inhibitors 2021"
Deadline for manuscript submissions: 31 July 2021.
Interests: design; synthesis and biological evaluation of heterocyclic compounds for therapeutic purposes (mycology, parasitology, and cancer); inhibitors of kinase signaling pathways; ADMET properties of molecules of biological interest
Special Issues and Collections in MDPI journals
In the last decade, about 300 protein kinase inhibitors have been involved in clinical trials and 49 were recently approved by the US Food and Drug Administration (FDA), mostly tyrosine kinase inhibitors, and mainly for cancer therapy. In the same period, targeting kinase pathways has emerged as a promising strategy in the fight against infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites, or fungi. Protein kinase inhibitors were also considered as potential drugs to combat CNS disorders.
This Special Issue will showcase the recent trends in the field of drug discovery of kinase inhibitors. In addition, review articles, research articles, and short communications will highlight the efforts of medicinal chemists to propose new molecules endowed with kinase inhibition properties and the strategies to enhance the activity profile of the existing pipeline.
Repurposing human kinase inhibitors also gained attention to create new active compounds.
Prof. Dr. Pascal Marchand
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- protein kinase inhibitors
- medicinal chemistry
- infectious diseases
- CNS disorders
- repurposing approach
- allosteric inhibitors